79 80

25

- **6**. The crystalline form of claim **1**, wherein the X-ray powder diffraction (XRPD) pattern further comprises 2-Theta peaks at $13.6\pm0.1^{\circ}$ and $16.1\pm0.1^{\circ}$.
- 7. The crystalline form of claim 1, wherein the X-ray powder diffraction (XRPD) pattern further comprises 5 2-Theta peaks at 13.6±0.1° and 21.6±0.1°.
- **8**. The crystalline form of claim **1**, wherein the X-ray powder diffraction (XRPD) pattern further comprises 2-Theta peaks at $16.1\pm0.1^{\circ}$ and $21.6\pm0.1^{\circ}$.
- 9. The crystalline form of claim 1, wherein the crystalline 10 form has Infrared (IR) spectrum weak peaks at about 1584 cm⁻¹, about 1240 cm⁻¹, about 1147 cm⁻¹, about 1134 cm⁻¹, about 1099 cm⁻¹, and about 1067 cm⁻¹.
- 10. The crystalline form of claim 1, wherein the crystalline form has a melting temperature of about 155-156° C. 15
- 11. The crystalline form of claim 1, wherein the crystalline form has a DSC thermogram with an endotherm having an onset at about 154° C. and a peak at about 157° C. and an exotherm at about 159° C.
- 12. The crystalline form of claim 1, wherein the crystal- 20 line form is non-hygroscopic.
- 13. The crystalline form of claim 1, wherein the crystalline form has an observed aqueous solubility of about 0.013 mg/mL at about pH 8.

* * *